Pfizer Inc. Beats Q1 Estimates on Strong Product Portfolio
Pfizer Inc. (NYSE: PFE) reported first-quarter earnings that exceeded Wall Street expectations, supported by solid growth across its recently launched and acquired products.
Earnings and Revenue Top Forecasts
The pharmaceutical company posted adjusted earnings per share (EPS) of $0.75, outperforming analyst estimates of $0.72. Revenue came in at $14.5 billion, beating projections of $13.84 billion and marking a 2% operational increase from $13.7 billion in the same period last year.
Excluding COVID-19 products such as Comirnaty and Paxlovid, revenue grew 7% on an operational basis. Meanwhile, Pfizer’s portfolio of newly launched and acquired products delivered an impressive 22% year-over-year operational growth.
Following the announcement, shares edged up 0.2%.
CEO Highlights Strong Start to 2026
CEO Albert Bourla expressed confidence in the company’s outlook, emphasizing continued momentum across its pipeline.
“We’re off to a strong start in 2026, reinforcing our confidence in navigating this critical period for Pfizer,” he said. “Our R&D pipeline is progressing across multiple fronts, with positive late-stage results and encouraging mid-stage developments, particularly in oncology and obesity.”
Key Growth Drivers Across Portfolio
Revenue gains were led by several high-performing products. Padcev rose 39% operationally, while Eliquis increased 8%. Oncology biosimilars surged 52%, and Nurtec climbed 41%.
However, these gains were partially offset by continued declines in COVID-related products. Comirnaty revenue fell 59% operationally, while Paxlovid dropped 63%.
Full-Year Guidance Reaffirmed
Pfizer maintained its full-year 2026 outlook, forecasting revenue between $59.5 billion and $62.5 billion. The company also expects adjusted EPS to range from $2.80 to $3.00.
The midpoint of this earnings guidance, at $2.90, comes slightly below the current analyst consensus of $2.96.
